An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

S&P 500 surges in H1 2025; explore AI leaders & ETFs for H2. Click to learn more about stocks to avoid and tips to navigate market volatility.

Plant scientists have used a standard "gene gun" since 1988 to genetically modify crops for better yield, nutrition, pest ...

Opioid addicts covered by Medicare and Medicaid are less likely to receive the mental health and substance use treatment that ...